semaglutide bone density loss A study presented at the #AAOS2026 Annual Meeting revealed GLP-1 receptor agonist use was associated with a 29% higher risk of osteoporosis after five years. As these medications become more widely used CT shows body composition changes

This press release appeared here first:

At this time, the glycolytic rate of tumour cells in the hypoxic area increases, producing significant lactate, which is then converted into pyruvate by the oxidation of MCT1 and LDHB oxidation and accelerates oxidative phosphorylation of tumour cells in the oxygen-containing region, which realizes the metabolic symbiosis of hypoxic and oxygen-containing cancer cells

J.StentenbachM.KariminejadA.et al (2018)

- Ed Lee is an Orlando-based endocrinologist who is hopeful for compounding approvals, especially for BPC-157, which is popular in the wellness community for its purported ability to repair tissues, including muscles and ligaments

Our guide to preventing muscle loss on GLP-1 medications is a great place to start